Association of vascular endothelial growth factor-C, plasma angiotensinogen and left ventricular hypertrophy in patients with hemodialysis.

Autor: Yeter HH; Department of Nephrology, Hacettepe University Faculty of Medicine, Ankara, Turkey., Levent M; Department of Geriatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey., Sahiner L; Department of Cardiology, Hacettepe University Faculty of Medicine, Ankara, Turkey., Yildirim T; Department of Nephrology, Hacettepe University Faculty of Medicine, Ankara, Turkey., Yilmaz R; Department of Nephrology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Jazyk: angličtina
Zdroj: Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy [Ther Apher Dial] 2024 Dec; Vol. 28 (6), pp. 904-911. Date of Electronic Publication: 2024 Jun 18.
DOI: 10.1111/1744-9987.14178
Abstrakt: Introduction: This study aims to examine the relationship between fluid overload, Vascular Endothelial Growth Factor C (VEGF-C), plasma Angiotensinogen (pAGT), and echocardiography findings in hemodialysis patients.
Methods: This was a single-center, cross-sectional study. Patients were divided into two groups according to mid-week inter-dialytic weight gain (mIDWG): (1) mIDWG ≤3% and (2) mIDW >3%.
Results: A total of 55 patients were enrolled in this study. While the mean pAGT and left ventricular mass index were significantly higher in patients with mIDWG >3% compared to patients with mIDWG ≤3%, VEGF-C was similar between groups. pAGT ≥76.8 mcg/L, VEGF-C ≤175.5 pg/ML, and pAGT /VEGF-C ≥0.45 were significant cut-offs for the prediction of left ventricular hypertrophy(LVH). Univariate logistic regression analysis revealed that these cut-off values were significantly associated with LVH.
Conclusion: Renin-angiotensin-aldosterone system activation may persist in hemodialysis patients with excessive IDWG. Additionally, pAGT and VEGF-C could be risk factors for the development of LVH.
(© 2024 International Society for Apheresis and Japanese Society for Apheresis.)
Databáze: MEDLINE
Externí odkaz: